Patients with Alzheimer’s disease (AD) experience a slow progressive decline in memory and cognitive ability, among other symptoms, due to the spread of damage in the brain. Generally, the disease is ...

Namzaric (donepezil and memantine), also known as MDX-8704, ADS-8704, and Arimenda, is an approved therapy for moderate to severe Alzheimer’s disease. Allergan markets the treatment in the U.S. and ...

While Alzheimer’s disease (AD) has no cure, five prescription medicines have been approved by the U.S. Food and Drug Administration (FDA) to treat disease symptoms that impact thinking and memory.

Being started on a smaller dose of the approved early Alzheimer’s disease therapy Kisunla (donanemab) — by shifting one vial from the first to the third infusion treatment — reduces the risk of ARIA-E ...

The approved drugs for Alzheimer’s disease do not address the underlying cause of the disease, but instead treat only the symptoms. However, there is a vast array of experimental treatments that are ...

As a disease that is best detected and treated early after onset, Alzheimer disease is characterized by a variety of aberrantly regulated proteins and molecules, which once identified can be used as ...

One of the hallmarks of Alzheimer’s disease is the formation of protein plaques and tangles between nerve cells. These are made of so-called beta-amyloid fragments that stick together and accumulate ...

Alzheimer’s disease (AD) is an irreversible and progressive neurological disorder, and the most common type of dementia. It is caused by damage to the brain and often first appears as minor changes in ...

Both of my parents, Ruth and Jim Page Sr., have passed from this life to the next. They were tremendous people who loved each other and their children profoundly. They had many gifts, separately and ...

Experimental treatments being developed to address the underlying cause of Alzheimer’s disease mostly target beta-amyloid plaques and tau protein tangles, which are thought to be the main players in ...